Serum sphingolipids reflect the severity of chronic HBV infection and predict the mortality of HBV-acute-on-chronic liver failure

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Qu, Feng ^a   Zheng, Su Jun ^b   Liu, Shuang ^b   Wu, Cai Sheng ^a   Duan, Zhong Ping ^b   Zhang, Jin Lan ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CERAMIDE; LIPIDOME; SPHINGOLIPID;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; BIOMETRY; BLOOD SAMPLING; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEPATITIS B; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLITE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; PROGNOSIS; SURVIVOR; TANDEM MASS SPECTROMETRY; BLOOD; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SURVIVAL; VIROLOGY;

ACUTE-ON-CHRONIC LIVER FAILURE; ADULT; BIOLOGICAL MARKERS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SPHINGOLIPIDS; SURVIVAL ANALYSIS;

EID: 84922999129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104988     Document Type: Article

References (41)

1. Ganem D, Prince AM (2004) Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350: 1118-1129. (Pubitemid 38298992)
2. Organization WH (2012) World Health Organization Fact Sheet 204 dex. (Revised July 2012). http://wwwwhoint/mediacentre/factsheets/fs204/en/indexhtml.
3. Jalan R, Williams R (2002) Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 20: 252-261. (Pubitemid 34195668)
4. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, et al. (2012) Acute-on chronic liver failure. J Hepatol 57: 1336-1348.
5. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, et al. (2009) Acute-onchronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 3: 269-282.
6. Diamond DL, Syder AJ, Jacobs JM, Sorensen CM, Walters KA, et al. (2010) Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog 6: e1000719.
7. Lorizate M, Krausslich HG (2011) Role of lipids in virus replication. Cold Spring Harb Perspect Biol 3: a004820.
8. Merrill AH, Jr., Stokes TH, Momin A, Park H, Portz BJ, et al. (2009) Sphingolipidomics: a valuable tool for understanding the roles of sphingolipids in biology and disease. J Lipid Res 50 Suppl: S97-102.
9. Moles A, Tarrats N, Morales A, Domínguez M, Bataller R, et al. (2010) Acidic Sphingomyelinase Controls Hepatic Stellate Cell Activation and in Vivo Liver Fibrogenesis. CORD Conference Proceedings 177: 1214-1224.
10. Llacuna L, Mari M, Garcia-Ruiz C, Fernandez-Checa JC, Morales A (2006) Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. Hepatology 44: 561-572. (Pubitemid 44433712)
11. Morales A, Mari M, Garcia-Ruiz C, Colell A, Fernandez-Checa JC (2012) Hepatocarcinogenesis and ceramide/cholesterol metabolism. Anticancer Agents Med Chem 12: 364-375.
12. Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, et al. (2011) Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 60: 695-701.
13. Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, et al. (2008) Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 82: 5715-5724. (Pubitemid 351822247)
14. Umehara T, Sudoh M, Yasui F, Matsuda C, Hayashi Y, et al. (2006) Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun 346: 67-73. (Pubitemid 43884734)
15. Tatematsu K, Tanaka Y, Sugiyama M, Sudoh M, Mizokami M (2011) Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication. J Med Virol 83: 587-593.
16. Brice SE, Cowart LA (2011) Sphingolipid metabolism and analysis in metabolic disease. Adv Exp Med Biol 721: 1-17.
17. Merrill AH, Jr. (2011) Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111: 6387-6422.
18. Marrero J, Martinez FJ, Hyzy R (2003) Advances in critical care hepatology. Am J Respir Crit Care Med 168: 1421-1426. (Pubitemid 38037323)
19. Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association (2005) [The guidelines of prevention and treatment for chronic hepatitis B]. Chinese journal of hepatology 13: 881-891.
20. Liver Failure and Artificial Liver Group, Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association (2006) [Diagnostic and treatment guidelines for liver failure]. Chinese journal of hepatology 14: 643-646.
21. Qu F, Wu C-S, Hou J-F, Jin Y, Zhang J-L (2012) Sphingolipids as New Biomarkers for Assessment of Delayed-Type Hypersensitivity and Response to Triptolide. PLoS ONE 7: e52454.
22. Eriksson L, Byrne T, Johansson E, Trygg J, Vikström C (2013) Multi- and Megavariate Data Analysis Basic Principles and Applications: Umetrics Academy; 3rd Edition edition (October 10, 2013).
23. Jia W (2009) Medical Metabonomics. Shanghai: Shanghai Scientific & Technical Publishers.
24. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
25. Garg H, Kumar A, Garg V, Sharma P, Sharma BC, et al. (2012) Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis 44: 166-171.
26. Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, et al. (2009) Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat 16: 464-470.
27. Zheng YB, Xie DY, Gu YR, Yan Y, Wu YB, et al. (2012) Development of a sensitive prognostic scoring system for the evaluation of severity of acute-onchronic hepatitis B liver failure: a retrospective cohort study. Clin Invest Med 35: E75-85.
28. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, et al. (1997) Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 157: 792-796. (Pubitemid 27164455)
29. Freeman RB, Jr., Wiesner RH, Harper A, McDiarmid SV, Lake J, et al. (2002) The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 8: 851-858. (Pubitemid 35012300)
30. Yu J-W, Sun L-J, Zhao Y-H, Li S-C (2008) Prediction value of model for endstage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. Journal of Gastroenterology and Hepatology 23: 1242-1249.
31. Chatzakos V, Rundlof AK, Ahmed D, de Verdier PJ, Flygare J (2012) Inhibition of sphingosine kinase 1 enhances cytotoxicity, ceramide levels and ROS formation in liver cancer cells treated with selenite. Biochem Pharmacol 84: 712-721.
32. Mari M, Fernandez-Checa JC (2007) Sphingolipid signalling and liver diseases. Liver Int 27: 440-450. (Pubitemid 46534565)
33. Malhi H, Gores GJ, Lemasters JJ (2006) Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43: S31-44.
34. Sun WY, Bonder CS (2012) Sphingolipids: A Potential Molecular Approach to Treat Allergic Inflammation. Journal of Allergy 2012: 1-14.
35. Wu XX, Sun Y, Guo WJ, Gu YH, Wu XF, et al. (2012) Rebuilding the balance of STAT1 and STAT3 signalings by fusaruside, a cerebroside compound, for the treatment of T-cell-mediated fulminant hepatitis in mice. Biochem Pharmacol 84: 1164-1173.
36. Bertoletti A, D'Elios MM, Boni C, De Carli M, Zignego AL, et al. (1997) Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 112: 193-199. (Pubitemid 27009002)
37. Malagarie-Cazenave S, Andrieu-Abadie N, Segui B, Gouaze V, Tardy C, et al. (2002) Sphingolipid signalling: molecular basis and role in TNF-alpha-induced cell death. Expert Rev Mol Med 4: 1-15.
38. Seijo S, Lozano JJ, Alonso C, Reverter E, Miquel R, et al. (2013) Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension. Am J Gastroenterol.
39. Trygg J, Wold S (2002) Orthogonal projections to latent structures (O-PLS). Journal of Chemometrics 16: 119-128.
40. Dudley JT, Butte AJ (2010) Biomarker and drug discovery for gastroenterology through translational bioinformatics. Gastroenterology 139: 735-741, 741 e731.
41. Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, et al. (2006) Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44: 326-334. (Pubitemid 44214871)